Industry pharmaceutical company Headquarters Oss | Founded November 2007 | |
 | ||
Parent organizations Schering-Plough, Merck & Co., P.T. Schering Plough Indonesia Founders Ernst Laqueur, Saal van Zwanenberg, Jacques van Oss | ||
Organon was a pharmaceutical company headquartered in Oss, Netherlands. In November 2007, Schering-Plough Corporation, based in New Jersey, USA, acquired Organon, active pharmaceutical ingredient producer Diosynth (separate from Organon until 2004), and its veterinary pharmaceutical sister company Intervet from Akzo Nobel. In November 2009, Schering-Plough merged with Merck & Co. under the name Merck & Co., known as Merck Sharp & Dohme or MSD outside the United States and Canada. Organon deals in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, HRT and anesthesia. Organon sells to international markets.
Contents
History
Organon was founded by Dr. Saal van Zwanenberg in Oss, the Netherlands, in 1923 as Zwanenberg-Organon. Its first product was insulin in 1923. In the thirties it manufactured estrogens. In 1948, Organon acquired the Newhouse research site in Scotland, United Kingdom. The production of cortisone was initiated in 1953. In 1962 it bought the stock of the Nederlandsche Cocaïnefabriek. The now named Koninklijke Zwanenberg-Organon (KZO) fused with the fibre producer AKU in 1969 to become AKZO, later Akzo Nobel. Organon was the human health care business unit of Akzo Nobel and transferred its headquarters to New Jersey, USA while the main headquarters of Akzo Nobel remained in Arnhem, and has since moved to Amsterdam. Manufacturing facilities are in the Netherlands, Germany, the United Kingdom, Ireland, China, Japan, and the USA.
Products
Products include: Bridion, Esmirtazapine, Remeron, Remeron SolTab, Sustanon, Deca-Durabolin, Pregnyl, Implanon, NuvaRing, Marvelon, Desolett and a variety of other contraceptive products.
Research compounds
During its period of independent operation, Organon developed a large number of compounds which were never adopted for medical use, but continue to be used for a variety of scientific research. Notable compounds include:
Kickback scandal
On Oct. 16, 2014, the government of the United States charged Organon with misrepresentation of drug prices and providing improper financial incentives (kickbacks) to nursing homes for market-shares discounts to encourage the use of Remeron. Organon paid $622,350 in restitution under the Federal Anti-Kickback Statute.